Archive for March, 2012

New paradigms in drug R&D: A personal perspective

The Author discusses the recent productivity problems in the pharmaceutical industry, in the context of his 30 year career, and the current responses of the industry driven strongly by disaggregation of the historic R&D model, new fluidites of capi…


Click here for reuse options!
Copyright 2012 Biotechblog

The Art of the Cap Table

This article provides an overview of the impact of raising capital on the equity ownership structure of a biotechnology company. The equity ownership structure as captured in a table of capitalization determines how the fruits of success will be divide…


Click here for reuse options!
Copyright 2012 Biotechblog

The Pitch to Investors and Partners

This article covers the essentials of constructing and delivering a “pitch” of a business opportunity to potential investors or corporate partners.  We advocate constructing an effective pitch first and then using that as a guide to prepare your b…


Click here for reuse options!
Copyright 2012 Biotechblog

What Every Biotech Entrepreneur Needs to Know about VC Due Diligence

Due diligence, as it applies to venture capital, is actually imprecise. Origins of the term are based in banking case law. Due diligence to the attorney is more of a precise concept. A better term is “homework.” Better indeed, because the burden of…


Click here for reuse options!
Copyright 2012 Biotechblog

Building Teams in Entrepreneurial Companies

This article focuses on the essentials of building effective, collaborative, team-based organizations. The entrepreneurs and innovators who found and build technology-based organizations comprise out target audience, but most specifically we address th…


Click here for reuse options!
Copyright 2012 Biotechblog

Partnering With the NIH: Now Part of the “Value Proposition” for Start-ups

For many years the United States has led the world in government support for non-military research and development (R&D), especially support for work that directly relates to health and human development.  A focal point for such federal investment…


Click here for reuse options!
Copyright 2012 Biotechblog

Transition from the Lab to the Clinic

Before considering the specific regulatory requirements and expectations relating to your product it is informative to understand who regulates and why. Full details at the Journal of Commercial Biotechnology


Click here for reuse options!
Copyright 2012 Biotechblog

Strategic Engagement of the Science-Business Media

As surely as the bio-enterprise can benefit from positive media coverage, it cannot thrive in the face of unanswered negative and/or inaccurate media attention. On all counts, the bio-enterprise must be able to strategically engage with the media at ev…


Click here for reuse options!
Copyright 2012 Biotechblog

The Basics of Coverage, Coding, and Reimbursement

The process of commercializing a new item or service in the U.S. health care market involves three distinct but necessary components: coverage, coding, and reimbursement.  This article provides an overview of these processes and the challenges in succ…


Click here for reuse options!
Copyright 2012 Biotechblog

Valuation Methods in Early-Stage Biotechnology Enterprises: The “Venture Capital Method” at Work

Valuation approaches to biotechnology companies by angel investors and venture capitalists often appear to the entrepreneurs to be based on voodoo rather than sound principles of finance. While there may be some truth to that perception, there is actua…


Click here for reuse options!
Copyright 2012 Biotechblog

%d bloggers like this: